Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014 Nov;13(11):1108-13. [Pubmed]
Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016 Oct;15(11):1182-94. [Pubmed]
Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013 Nov;9(11):617-28. [Pubmed]
Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, Sobue G. Amyotrophic lateral sclerosis. Lancet. 2022 Oct 15;400(10360):1363-80. [Pubmed]
Galvin M, Ryan P, Maguire S, Heverin M, Madden C, Vajda A, et al. The path to specialist multidisciplinary care in amyotrophic lateral sclerosis: a population-based study of consultations, interventions and costs. PLoS One. 2017 Jun 22;12(6):e0179796. [Pubmed]
Goutman SA, Hardiman O, Al-Chalabi A, Chió A, Savelieff MG, Kiernan MC, Feldman EL. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 2022 May;21(5):480-93. [Pubmed]
Hannaford A, Byth K, Pavey N, Henderson RD, Mathers S, Needham M, et al. Clinical and neurophysiological biomarkers of disease progression in amyotrophic lateral sclerosis. Muscle Nerve. 2023 Jan;67(1):17-24. [Pubmed]
Kiernan MC, Vucic S, Talbot K, McDermott CJ, Hardiman O, Shefner JM, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021 Feb;17(2):104-18. [Pubmed]
Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. 2016 Jun;87(6):628-32. [Pubmed]
Lee JD, Heshmat S, Heggie S, Thorpe KA, McCombe PA, Henderson RD. Clinical and electrophysiological examination of pinch strength in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2021 Jan;63(1):108-13. [Pubmed]
Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020 Oct;27(10):1918-29. [Pubmed]
Mitchell JD, Callagher P, Gardham J, Mitchell C, Dixon M, Addison-Jones R, et al. Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)--a 20-year review: can we do better? Amyotroph Lateral Scler. 2010 Dec;11(6):537-41. [Pubmed]
Quinn C, Elman L. Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases. Continuum (Minneap Minn). 2020 Oct;26(5):1323-47. [Pubmed]
Saberi S, Stauffer JE, Schulte DJ, Ravits J. Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. Neurol Clin. 2015 Nov;33(4):855-76. [Pubmed]
Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020 Aug;131(8):1975-8. [Pubmed]
Sturmey E, Malaspina A. Blood biomarkers in ALS: challenges, applications and novel frontiers. Acta Neurol Scand. 2022 Oct;146(4):375-88. [Pubmed]
Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014 Nov;10(11):661-70. [Pubmed]
Taga A, Maragakis NJ. Current and emerging ALS biomarkers: utility and potential in clinical trials. Expert Rev Neurother. 2018 Nov;18(11):871-86. [Pubmed]
Westeneng HJ, Al-Chalabi A, Hardiman O, Debray TP, van den Berg LH. The life expectancy of Stephen Hawking, according to the ENCALS model. Lancet Neurol. 2018 Aug;17(8):662-3. [Pubmed]
Witzel S, Mayer K, Oeckl P. Biomarkers for amyotrophic lateral sclerosis. Curr Opin Neurol. 2022 Oct 1;35(5):699-704. [Pubmed]